Avapag 20mg
৳ 260
Pregnancy & Lactation
Lactation: There are no information regarding the presence of Avatrombopag in human milk, the effects on the breastfed child, or the effects on milk production. Due to the potential for serious adverse reactions in a breastfed child from Avatrombopag, breastfeeding is not recommended during treatment with Avatrombopag and for at least 2 weeks after the last dose.
Precautions & Warnings
Use in Special Populations
Geriatric Use: Reported clinical experience has not identified differences in responses between the elderly and younger patients.
Overdose Effects
Storage Conditions
Buy 15 products and get ৳ 20 discount
Description
Indications
Treatment of Thrombocytopenia in Patients with Chronic Immune Thrombocytopenia (ITP): Avapag is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.
Pharmacology
Pharmacodynamics: Platelet Response: Avatrombopag resulted in dose- and exposure-depen- dent elevations in platelet counts in adults. The onset of the platelet count increase was observed within 3 to 5 days of the start of a 5-day treatment course, with peak effect observed after 10 to 13 days. Subsequently, platelet counts decreased gradually, returning to near baseline values after 35 days.
Pharmacodynamics: Cardiac Electrophysiology: At exposures similar to that achieved at the 40 mg and 60 mg dose, Avatrombopag did not prolong the QT interval to any clinically relevant extent. Mean QTc prolongation effects >20 ms are not anticipated with the highest recommended therapeutic dosing regimen based on analysis of data from the pooled clinical trials in patients.
Dosage & Administration
- Platelet count less than 40X109/L: 60 mg (3 tablets) for 5 days
- Platelet count 40 to less than 50X109/L: 40 mg (2 tablets) for 5 days
Recommended Dosage for Patients with Chronic Immune Thrombocytopenia: Initial Dose Regimen: Begin Avatrombopag at a starting dose of 20mg (1tablet) once daily with food. Avatrombopag Dose Adjustments for Patients with Chronic Immune Thrombocytopenia-
Less than 50 after at least 2 weeks of Avatrombopag x 109/L: Increase One Dose Level. Wait 2 weeks to assess the effects of this regimen and any subsequent dose adjustments.
Between 200 and 400 x 109/L: Decrease One Dose Level. Wait 2 weeks to assess the effects of this regimen and any subsequent dose adjustments.
Greater than 400 x 109/L: Stop Avatrombopag. Increase platelet monitoring to twice weekly. When platelet count is less than 150 x10 9 /L, decrease One Dose Level per Table 3 and reinitiate therapy.
Less than 50 after 4 weeks of Avatrombopag 40 mg once daily x 109/L: Discontinue Avatrombopag.
Greater than 400 after 2 weeks of Avatrombopag 20 mg weekly x 109/L: Discontinue Avatrombopag.
Or, as directed by the registered physician.
Interaction
Moderate or Strong Dual Inhibitors of CYP2C9 and CYP3A4: Concomitant use with a moderate or strong dual inhibitor of CYP2C9 and CYP3A4 increases Avapag AUC, which may increase the risk of Avapag toxicities. Reduce the starting dosage of Avapag when used concomitantly with a moderate or strong dual inhibitor of CYP2C9 and CYP3A4.
Moderate or Strong Dual Inducers of CYP2C9 and CYP3A4: Concomitant use with a moderate or strong dual inducer of CYP2C9 and CYP3A4 decreases Avapag AUC, which may reduce Avapag efficacy.
Increase the recommended starting dosage of Avapag when used concomitantly with a moderate or strong dual inducer of CYP2C9 and CYP3A4.
Reviews
There are no reviews yet.